Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumabin HR-positive, Her2-positive Metastatic Breast Cancer (ASPIRE)
Sponsor: |
Mt. Sinai |
Enrolling: |
Female Patients Only |
IRB Number: |
AAAS3060 |
U.S. Govt. ID: |
NCT03304080 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab, and pertuzumab to women with hormone receptor-positive, HER2-positive metastatic breast cancer. This combination of medications represents an all-biologic approach and avoids chemotherapy as first-line treatment of this disease.
This study is closed
Investigator
Melissa Accordino, MD
Are you a woman of 18 years of age or older? |
Yes |
No |
Have you been diagnosed with HR positive, HER2 positive, Stage IV breast cancer? |
Yes |
No |
Have you had any prior systemic treatment for metastatic breast cancer? |
Yes |
No |